1453874-63-9Relevant academic research and scientific papers
Doxorubicin-antioxidant co-drugs
Chegaev, Konstantin,Riganti, Chiara,Rolando, Barbara,Lazzarato, Loretta,Gazzano, Elena,Guglielmo, Stefano,Ghigo, Dario,Fruttero, Roberta,Gasco, Alberto
, p. 5307 - 5310 (2013)
Doxorubicin-antioxidant multitarget compounds 6 and 7 were obtained by combining doxorubicin (DOX) with caffeic and ferulic acids through an ester linkage at C-14. The products were studied in in vitro models of cardiomyocytes and breast cancer cells, characterized by different degrees of resistance to DOX, due to different expressions of ATP binding cassette (ABC) transporters. Compound 7 was found to be less toxic than DOX in cardiomyocytes and to display the same possibly higher toxicity against the resistant breast cancer cells. This result shows that appropriate DOX-antioxidant co-drugs can limit the onset of cardiac damage, a significant side-effect of DOX, without impairing the antitumor activity of the parent antibiotic.
